Site Navigation
Categories:
Nucleoside analog reverse transcriptase inhibitors
All articles with unsourced statements
Articles with unsourced statements since October 2008

Summary Of: AZT

AZT was originally intended to treat... of AZT was subsequently conducted by Burroughs... in which it was shown that AZT could prolong the life of patients with AIDS... The crystal structure of AZT was reported by Alan Howie... AZT may be used in combination with other antiretroviral medications to substantially reduce the risk of... AZT is also recommended as part of a regimen to prevent... AZT has been shown to reduce this risk to approximately 8... AZT has been shown to work additively or synergistically with many antiviral agents such as acyclovir... AZT does not destroy the HIV infection... During prolonged AZT treatment HIV has the ability to gain an increased resistance to AZT by... showed that AZT could not impede the resumption of virus production... and eventually cells treated with AZT produced viruses as much as the untreated cells... physicians generally recommend that AZT be given in combination with another... AZT in oral and injectable form... AZT in oral and injectable form... AZT works by inhibiting the action of... Cellular enzymes convert AZT into the effective 5... AZT has a 100... AZT has been the target of some controversy due to the nature of the patent process... other drug companies to manufacture and market generic AZT without having to pay... forms of AZT for sale in the U...

Encyclodia Page On: AZT

These Are Links To Other Documents
| | IUPAC | CAS number | ATC code | J05 | PubChem | DrugBank | Formula | C | H | N | O | Mol. mass | SMILES | Bioavailability | Protein binding | Metabolism | Hepatic | Half life | Excretion | Renal | Pregnancy cat. | US | Legal status | Routes | INN | nucleoside analog reverse transcriptase inhibitor | antiretroviral drug | HIV | Combivir | Trizivir | analog | thymidine | Jerome Horwitz | Wayne State University School of Medicine | US | National Institutes of Health | grant | cancer | Samuel Broder | Hiroaki Mitsuya | Robert Yarchoan | National Cancer Institute | GlaxoSmithKline | in vitro | clinical trial | CD4 | placebo | randomized trial | Food and Drug Administration | March 20 | 1987 | anemia | antiretroviral drugs | highly active antiretroviral therapy | Aberdeen University | hydrogen bond | | | mother-to-child transmission | cesarean section | anemia | bone marrow suppression | erythropoietin | darbepoetin | mitochondria | ribavirin | hepatic | glucuronidation | indomethacin | acetylsalicylic acid | trimethoprim | mutation | reverse transcriptase | citation needed | reverse transcriptase inhibitor | protease inhibitor | non-nucleoside reverse transcriptase inhibitor | | | reverse transcriptase inhibitors | reverse transcriptase | enzyme | DNA | RNA | DNA | cell | provirus | lipophilic | cell membranes | diffusion | blood-brain barrier | DNA polymerase | cell division | mitochondria | myositis | Public Citizen | United States Court of Appeals for the Federal Circuit | Burroughs Wellcome | AIDS Healthcare Foundation | patent | public domain | GlaxoSmithKline | generic | New York Times | September 20 | 1986 | March 17 | 2008 | doi | doi | doi | doi | doi | doi | doi | doi | doi | The Best Democracy Money Can Buy | Greg Palast | v | d | Antivirals | HIV | HAART | J05 | Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
| Abacavir (ABC) | Emtricitabine (FTC) | KP-1461 | Lamivudine (3TC) | Tenofovir | Didanosine (ddI) | Apricitabine | Stampidine | Elvucitabine | Racivir | Amdoxovir | Stavudine (d4T) | Zalcitabine (ddC) | Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
| Efavirenz | Nevirapine | Etravirine | Rilpivirine | Loviride | Delavirdine | Protease Inhibitors (PI) | Atazanavir | Brecanavir | Fosamprenavir | Lopinavir | Darunavir | Nelfinavir | Ritonavir | Saquinavir | Tipranavir | Amprenavir | Indinavir | Entry/fusion inhibitors | Aplaviroc | Enfuvirtide | Maraviroc | Vicriviroc | PRO 140 | Ibalizumab | Integrase inhibitors | Raltegravir | Elvitegravir | Maturation inhibitors | Bevirimat | Vivecon | Combined formulations | Combivir | Atripla | Trizivir | Truvada | Kaletra | Epzicom | Abzyme | Calanolide A | Ceragenin | Cyanovirin-N | Diarylpyrimidines | Epigallocatechin gallate (EGCG) | Foscarnet | Globoidnan A | Griffithsin | Hydroxyurea | Miltefosine | Portmanteau inhibitors | Seliciclib | Synergistic enhancers | Tre recombinase | Zinc finger protein transcription factor | DHHS | first-line agent | clinical trials | FDA | Development | Category | Nucleoside analog reverse transcriptase inhibitors | All articles with unsourced statements | Articles with unsourced statements since October 2008 |
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "AZT".